WOBURN, Mass.–Cambridge Research & Instrumentation, Inc. (CRi) is pleased to announce that Richard K. Brown, Ph.D. and John P. McDonough have joined CRi’s Board of Directors. CRi is a leader in biomedical imaging solutions that generate disease-specific information from biological and clinical samples.

Dr. Brown has over twenty years experience in the life science industry, with a strong track record of growth and accomplishment in both management and business development roles. He is President & CEO of AVIA Biosystems. Prior to founding AVIA, he was President & CEO of MicroCal (now part of GE Healthcare), the world’s leading supplier of microcalorimeters to the life sciences from 2006-2009, and led its successful sale to GE Healthcare. Prior to that, he held various executive positions at Isis Pharmaceuticals from 2001-2006, including Vice President of Business Development and President of GeneTrove, the functional genomics division of Isis, where he was successful in establishing numerous partnerships with large pharmaceutical companies. Additionally, he held various executive positions at Discovery Partners International from 1995-2001, including President of IRORI where he participated in a successful IPO. Prior to DPI, Dr. Brown held various leadership positions with Zymark Corporation (now Caliper Life Sciences) from 1983-1995.

Mr. McDonough is a seasoned executive with extensive management, financial and M&A experience. He is President, CEO, and Board Director of T2 Biosystems, a venture-backed medical diagnostics company developing point-of-care platforms. Prior to T2, he held numerous executive positions in corporate development and operations at Cytyc Corporation from 2003-2006, including President of Cytyc Development Corporation where he led numerous multi-million dollar acquisitions including the negotiation of the $6.3 billion acquisition of Cytyc by Hologic, and the subsequent integration. Prior to that, he founded and served as CEO and Chairman of the Board for Soundbite Communications from 2000-2003, where he raised several rounds of venture funding and led a successful IPO. Mr. McDonough was also COO of Direct Hit Technologies from 1999-2000 until its sale to Ask Jeeves, President & CEO of Workgroup Technology Corporation from 1997-1999, and held numerous executive positions at Easel Corporation from 1985-1995, including President & CEO, until its successful merger with VMARK Software.

“We are very excited to have entrepreneurial executives as talented as Richard and John join our Board,” says CRi President & CEO George Abe. “I have no doubt that as our company continues to grow, their guidance will contribute greatly to our shareholder value.”

Cambridge Research & Instrumentation, Inc (CRi) is a leader in biomedical imaging, and is dedicated to providing comprehensive solutions that analyze disease-specific information from biological and clinical samples in the combined physiological, morphological, and biochemical context of intact tissues and organisms for a variety of applications. With over 80 patents pending and issued, CRi’s award-winning innovations are being utilized around the world to enable our customers to perform leading research and provide better healthcare.